From ArtVandelay on PR:
Dr. Jay Goldstein in the late 1970s and early 1980s claimed that cimetidine (Tagamet) and ranitidine (Zantac) were effective in combating herpes infections; particularly EBV.
Cimetidine, ranitidine, and Epstein-Barr virus infection. Goldstein JA. Ann Intern Med. 1986 Jul;105(1):139.
https://www.ncbi.nlm.nih.gov/pubmed/?term=(ranitidine[Title/Abstract])+AND+Goldstein+JA[Author]
Also, Treatment of chronic Epstein-Barr virus disease with H2 blockers. Goldstein JA. J Clin Psychiatry. 1986 Nov;47(11):572).
https://www.ncbi.nlm.nih.gov/pubmed/3021713
From zzz on PR:
The best documented, most scientific alternative EBV treatment (which should really be mainstream) is the one Dr. Jay Goldstein developed for treating his mononucleosis patients in 1979. He used Tagamet (an H(2) blocker), but once Zantac came out, he switched to that, because it had far fewer side effects. For 90% of his mono patients, Zantac 150 twice a day got rid of all mono symptoms in a day or two. Over the years, this treatment was done on well over a hundred patients. This treatment was also very helpful for 20% of his CFS patients.
There are papers published on this, but no clinical studies. Why? Here's Dr. Goldstein's explanation:
As a probably predictable aside, I should mention no one evinced the slightest curiosity about how these results [the rapid termination of LSD effects using niacin] were accomplished, and this "antidote" remains little known thirty years later, much like my discovery in 1979 that cimetidine made acute infectious mononucleosis in teenagers or adults (and varicella, too) resolve in one or two days. I am getting tired of whining about it, but hardly anyone is aware of this treatment, even now [in 2004, 25 years after its discovery]. Although I reported a 90 percent cure rate in over 100 patients (rather high for a placebo response), the results were "anecdotal". Naturally, I was unable to get a grant to perform a double-blind, placebo-controlled experiment. "But Tagamet (and later Zantac) is for ulcers," the reviewers would write. The fact that the chairman of the department of infectious diseases at the local medical school was my coinvestigator on the grant proposal did not grease the wheel at all.
And the drug companies wouldn't pay for such a study - the antivirals are so much more profitable than Zantac.